By blocking an enzyme linked to epigenetic regulation, Prelude hopes to cut off certain treatment-resistant cancers from the DNA splicing and proliferative mechanics necessary for tumor growth and survival.
Sanifit is breaking the mold in its native country: Back in June, it raised a massive €55.2 million ($62.9 million) series D round, smashing Spanish biotech VC records and ranking as one of the biggest life sciences raises in Europe for the year.
Quell has brought together experts in multiple fields to probe a question with far-reaching implications: What would happen if we applied CARs and other cell enhancements to regulatory T cells rather than effector T cells?
The commercial potential of CAR-Ts is constrained by a range of logistical and safety issues. Nkarta thinks engineered natural killer cells can eliminate those constraints, resulting in better therapies equipped to go mainstream.